Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Cyclic - C3  (3D View)
Global Stoichiometry: Homo 3-mer - A3 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 65108.39 
• Atom Count: 3428 
• Residue Count: 568 
• Unique protein chains: 1

5KWW

Crystal Structure of Inhibitor JNJ-53718678 In Complex with Prefusion RSV F Glycoprotein

• DOI: 10.2210/pdb5KWW/pdb

• Classification: VIRAL PROTEIN/INHIBITOR
• Organism(s): Human immunodeficiency virus 1, Human respiratory syncytial virus A (strain A2)
• Expression System: Homo sapiens


• Deposited: 2016-07-19 Released: 2017-08-02 
• Deposition Author(s): McLellan, J.S., Battles, M.B., Arnoult, E., Roymans, D., Langedijk, J.P.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.5 Å
• R-Value Free: 0.239 
• R-Value Work: 0.210 

Literature

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor.

Roymans, D., Alnajjar, S.S., Battles, M.B., Sitthicharoenchai, P., Furmanova-Hollenstein, P., Rigaux, P., Berg, J.V.D., Kwanten, L., Ginderen, M.V., Verheyen, N., Vranckx, L., Jaensch, S., Arnoult, E., Voorzaat, R., Gallup, J.M., Larios-Mora, A., Crabbe, M., Huntjens, D., Raboisson, P., Langedijk, J.P., Ackermann, M.R., McLellan, J.S., Vendeville, S., Koul, A.

(2017) Nat Commun 8: 167-167

• PubMed: 28761099 
• DOI: 10.1038/s41467-017-00170-x


• PubMed Abstract: 
  

Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly. Intervention with small-molecule antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compounds are approved today. Here we report the structure of JNJ-53718678 bound to respiratory syncytial virus fusion (F) protein in its prefusion conformation, and we show that the potent nanomolar activity of JNJ-53718678, as well as the preliminary structure-activity relationship and the pharmaceutical optimization strategy of the series, are consistent with the binding mode of JNJ-53718678 and other respiratory syncytial virus fusion inhibitors. Oral treatment of neonatal lambs with JNJ-53718678, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible. Together, these data suggest that JNJ-53718678 is a promising candidate for further development as a potential therapeutic in patients at risk to develop respiratory syncytial virus acute lower respiratory tract infection.Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.

---

Organizational Affiliation: 

Janssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. [e-mail].

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Fusion glycoprotein F0, Envelope glycoprotein chimera	F	568	Human immunodeficiency virus 1, Human respiratory syncytial virus A (strain A2) This entity is chimeric	Mutation(s): 0  Gene Names: F
Find proteins for M1E1E4 (Human immunodeficiency virus 1) Go to UniProtKB:  M1E1E4
Find proteins for P03420 (Human respiratory syncytial virus A (strain A2)) Go to UniProtKB:  P03420

Small Molecules

Ligands 4 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
SO4	F	SULFATE ION O4 S QAOWNCQODCNURD-UHFFFAOYSA-L
NHE	F	2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID N-CYCLOHEXYLTAURINE; CHES C8 H17 N O3 S MKWKNSIESPFAQN-UHFFFAOYSA-N
6YA	F	3-[[5-chloranyl-1-(3-methylsulfonylpropyl)indol-2-yl]methyl]-1-[2,2,2-tris(fluoranyl)ethyl]imidazo[4,5-c]pyridin-2-one C21 H20 Cl F3 N4 O3 S GTQTUABHRCWVLL-UHFFFAOYSA-N
NAG	F	N-ACETYL-D-GLUCOSAMINE C8 H15 N O6 OVRNDRQMDRJTHS-FMDGEEDCSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.5 Å
• R-Value Free: 0.239 
• R-Value Work: 0.210 
• Space Group: P 4₁ 3 2
• Diffraction Data DOI: 
  10.15785/SBGRID/478 SBGrid

Unit Cell:

Length (Å)	Angle (°)
a = 169.990	α = 90.00
b = 169.990	β = 90.00
c = 169.990	γ = 90.00

Software Package:

Software Name	Purpose
PDB_EXTRACT	data extraction
PHASER	phasing
PHENIX	refinement
iMOSFLM	data reduction
Aimless	data scaling

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2016-07-19 
• Released Date: 2017-08-02 
• Deposition Author(s): McLellan, J.S., Battles, M.B., Arnoult, E., Roymans, D., Langedijk, J.P.

Revision History 

• Version 1.0: 2017-08-02
  Type: Initial release
• Version 1.1: 2017-08-16
  Type: Database references